DuLac Farmaceutici, an Italian wellness company, is accelerating its push into the U.S. market with the announcement that its products are now available through OneLavi.com and its upcoming participation in the 2026 ECRM Vitamin, Weight Management & Sports Nutrition Session, scheduled for September 14-17 in Palm Beach Gardens, Florida. These moves are pivotal in DuLac's strategy to significantly expand its presence in the United States.
Having already established consumer demand through Amazon U.S., the company is adding a new e-commerce channel while preparing to introduce its brand and product portfolio to major U.S. retailers at ECRM. DuLac views the U.S. as a significant long-term growth market and is building a broader presence that combines established Amazon demand, expanded e-commerce availability, and direct engagement with retailers and distribution partners.
“ECRM comes at an important time for DuLac because we are making a major commitment to the U.S. market,” said Gabriele Bollani, Founder and CEO of DuLac Farmaceutici. “Amazon has demonstrated that American consumers are responding to our products, OneLavi gives us another important U.S. channel, and now we are ready to introduce DuLac to major retailers and build the partnerships that can take our expansion to the next level.”
The company enters this phase with a strong base of U.S. consumer demand. On Amazon, Arnica Gel 98% has garnered more than 13,000 customer reviews and an average 4.5-star rating, while the Dinaven line has received over 4,000 reviews and maintains a 4.6-star average. The addition of OneLavi represents the next step in broadening that footprint, offering another platform to introduce its Made in Italy portfolio to American consumers.
Participation at ECRM adds a crucial business-to-business dimension. During the session, DuLac will hold scheduled meetings with buyers from major health, specialty, food, drug, and mass retail channels, presenting its Italian-developed products, pharmaceutical heritage, and advanced manufacturing capabilities. Among the portfolio highlighted will be the high-concentration Arnica Gel 98% range and the Dinaven and Diosmin lines. The objective extends beyond additional points of distribution; DuLac aims to establish relationships that support a larger, more diversified U.S. retail presence.
DuLac brings more than 30 years of pharmaceutical industry expertise and pharmacy-channel experience in Italy to its U.S. expansion. Its capabilities include the proprietary Arnica Montana Arricchita™ project, indoor vertical farming, micronized Diosmin MPFF technology, solvent-free Supercritical CO₂ Extraction, and manufacturing under internationally recognized GMP and ISO quality frameworks. This combination of heritage, research, advanced production, and growing U.S. distribution lays the foundation for the next stage of growth.
With Amazon established, OneLavi now live, and ECRM meetings planned, DuLac is transitioning from initial market development to a broader national expansion strategy. The company's goal is to build a diversified U.S. presence across e-commerce, retail, wholesale, and other channels while introducing more American consumers to its brand and Italian-developed products.
